Across Europe, Janssen’s Zytiga Captures Patient Share in All Lines of Metastatic Castrate-Resistant Prostate Cancer, but Patient Share is Greatest in Second- and Third-Line Settings

Across Europe, Janssen’s Zytiga Captures Patient Share in All Lines of Metastatic Castrate-Resistant Prostate Cancer, but Patient Share is Greatest in Second- and Third-Line Settings

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed European oncologists are most concerned about the risk of myocardial infarction/stroke associated with long-term hormonal treatment for biochemically recurrent prostate cancer patients, but it is a rare adverse event. Osteoporosis is more frequently experienced and also a major concern among European urologists and oncologists. According to primary research findings from , surveyed European urologists and oncologists say that their biochemically recurrent patients are most likely to receive hormonal therapy alone, although radiotherapy (either alone, in combination with hormones, or with surgery) is also frequently administered.

Considering metastatic castrate-resistant prostate cancer (MCRPC), the majority of patients entering the MCRPC population are asymptomatic, according to European urologists, although European oncologists report, on average, that significantly fewer patients are asymptomatic. Across the EU5 Total, significantly more oncologists than urologists report that MCRPC asymptomatic/minimally symptomatic patients have visceral metastases. Nevertheless, the overall proportion of these patients with visceral metastases is less than a fifth.

With respect to performance of key agents in the MCRPC setting, European respondents score Zytiga the highest on most profiled attributes, including improving overall survival and in overall performance. Zytiga also scores best in low incidence of toxicities and convenience of delivery. Docetaxel scores the best with respect to familiarity and cost effectiveness.

“Surveyed urologists assign highest patient share for Zytiga in the third-line setting, and they report that only a minority of their patients receive Jevtana,” said Oncology Therapeutic Class Director, Andrew Merron, Ph.D. “According to all surveyed oncologists, more than half first-line symptomatic MCRPC patients receive docetaxel, nearly a third receive Zytiga in the second-line and nearly a quarter receive Jevtana in the third-line setting.”

is a syndicated report that examines current trends in the management of prostate cancer from the perspective of urologists and medical oncologists in Europe with a focus on analyzing their attitudes, perceptions and self-reported prescribing behavior. In addition, this report provides insight into the practice patterns, and current and projected use of various products. TreatmentTrends also evaluates perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. This study was fielded with a total of 314 urologists and oncologists across France, Germany, Spain, Italy and the United Kingdom via an online survey.

BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or . BioTrends is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.